Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Pfizer Inc.

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s PAXLOVID™ Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19
From Pfizer Inc.
Via Business Wire
Tickers PFE
FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Prices $31,000,000,000 Debt Offering
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Proposed Notes Offering
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Reports First-Quarter 2023 Results
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Approves PREVNAR 20®, Pfizer’s 20-valent Pneumococcal Conjugate Vaccine for Infants and Children
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Declares Second-Quarter 2023 Dividend
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Shareholders to Attend Virtual-Only 2023 Annual Meeting of Shareholders on April 27
From Pfizer Inc.
Via Business Wire
Tickers PFE
FDA Accepts Pfizer’s Supplemental New Drug Applications for BRAFTOVI + MEKTOVI
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
Tickers PFE
FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for Pfizer’s PAXLOVID™
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Accepts Biologics License Application for Pfizer’s Respiratory Syncytial Virus Maternal Vaccine Candidate for Priority Review
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
From Pfizer Inc.
Via Business Wire
Tickers PFE
FDA Approves Pfizer's Supplemental New Drug Application for CIBINQO® (abrocitinib)
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate
From Pfizer Inc.
Via Business Wire
Tickers PFE
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
From Pfizer Inc.
Via Business Wire
Tickers PFE
Pfizer Announces FDA and EMA Acceptance of Etrasimod Regulatory Submissions for Ulcerative Colitis
From Pfizer Inc.
Via Business Wire
Tickers PFE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.